BPX-01 Minocycline Topical Gel in the Treatment of Acne Vulgaris

ClinicalTrials.gov ID: NCT02815332

Public ClinicalTrials.gov record NCT02815332. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 10, 2026, 12:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Vehicle Controlled Study to Assess the Safety and Efficacy of BPX-01 Minocycline Topical Gel in the Treatment of Moderate to Severe Inflammatory Acne Vulgaris

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a 12-week, multi-center, double-blind, randomized, three-arm, vehicle-controlled study. Subjects will be randomized (1:1:1) to 1% or 2 % BPX-01 gel, or vehicle. Subjects will apply 1g of the gel as a thin film to the entire face at least 30 minutes before bedtime each night for 12 weeks. Lesion counts, IGA, and Patient-Reported Outcomes (PGI-S and PGI-I) will be performed to assess efficacy. Blood draws will be collected at baseline (Day 0), and at Weeks 4 and 12 to evaluate the level of minocycline in plasma. Safety will be assessed with the vital signs, brief physical examination, clinical laboratory tests, cutaneous tolerance score, incidence of minocycline-induced skin hyperpigmentation, incidence of visual disturbances and/or headaches suggestive of pseudotumor cerebri, and collection of adverse events.

Study identification

NCT ID: NCT02815332
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: BioPharmX, Inc.; Industry
Enrollment: 225 participants

Conditions and interventions

Conditions

Acne Vulgaris

Interventions

Drug

Eligibility (public fields only)

Age range: 9 Years to 40 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 31, 2016
Primary completion: Mar 23, 2017
Completion: Mar 23, 2017
Last update posted: Apr 13, 2017

2016 – 2017

United States locations

U.S. sites: 15
U.S. states: 11
U.S. cities: 15

Facility	City	State	ZIP	Site status
Not listed	Santa Monica	California	—	—
Not listed	Coral Gables	Florida	—	—
Not listed	Lake Mary	Florida	—	—
Not listed	Newnan	Georgia	—	—
Not listed	Louisville	Kentucky	—	—
Not listed	Las Vegas	Nevada	—	—
Not listed	Montclair	New Jersey	—	—
Not listed	New York	New York	—	—
Not listed	Highpoint	North Carolina	—	—
Not listed	Murfreesboro	Tennessee	—	—
Not listed	Nashville	Tennessee	—	—
Not listed	Pflugerville	Texas	—	—
Not listed	Plano	Texas	—	—
Not listed	San Antonio	Texas	—	—
Not listed	Spokane	Washington	—	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02815332, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 13, 2017 · Synced Sep 10, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02815332 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →